<DOC>
	<DOCNO>NCT00304772</DOCNO>
	<brief_summary>The purpose study verify equivalence clinical efficacy fluconazole micafungin treatment Candida bloodstream infection non-neutropenic patient .</brief_summary>
	<brief_title>Fluconazole Versus Micafungin Candida Bloodstream Infection Non-Neutropenic Patients</brief_title>
	<detailed_description>Candida bloodstream infection occur patient poor general condition poor prognosis attributable mortality 30 % . Clinical efficacy fluconazole treatment Candida bloodstream infection report clinical study , since 1985 place market . Fluconazole establish position first-line drug date . However , possibly associate increase use fluconazole , increase frequency Candida species strain low susceptibility fluconazole point . Micafungin , antifungal echinocandin different antifungal mechanism fluconazole , report show good vitro activity various Candida specie strain fluconazole resistance , comparative clinical efficacy fluconazole esophageal candidiasis , relatively low vitro activity certain Candida specie . There comparative study fluconazole versus micafungin Candida bloodstream infection .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Patients Candida specie isolate blood culture . Patients accompanied systemic infectious symptom period 24 hour ( h ) collection blood culture show positive result . Patients age 20 year old date registration . Patients receive systemic administration antifungal agent start administration within 48 h. Patients central venous ( CV ) catheter remove period 24 h collection blood culture show positive result registration , CV catheter remove within 72 h registration . Patients verify undrainable abscess diameter least 3 cm , impassable occlusive lesion , possibly attributable Candida specie . Patients write informed consent participate study obtain ( legally acceptable representative ) . Patients adequate neutrophil count hepatic/renal function blood test perform within 72 h registration . Patients history adverse reaction associate fluconazole micafungin . Patients treat fluconazole micafungin least 1 week within 12 week . Patients history detection fluconazole nonsusceptible Candida specie within 12 week . Patients neutrophil count predict decrease 500/mL . Patients treated terfenadine , triazolam , cisapride , ergotamine , contraindicate concomitant use fluconazole . Patients determine ineligible investigator .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Candida</keyword>
	<keyword>bloodstream infection</keyword>
	<keyword>fluconazole</keyword>
	<keyword>micafungin</keyword>
	<keyword>randomize control trial</keyword>
</DOC>